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Regulation of the redox state of protein disulfide isomerase (PDI) is critical for its various
catalytic functions. Here we describe a procedure utilizing isotope-coded affinity tag (ICAT)
technology and mass spectrometry that quantitates relative changes in the dynamic thiol and
disulfide states of human PDI. Human PDI contains six cysteine residues, four present in two
active sites within the a and a= domains, and two present in the b= domain. ICAT labeling of
human PDI indicates a difference between the redox state of the two active sites. Furthermore,
under auto-oxidation conditions an80% decrease in available thiols within the a domain was
detected. Surprisingly, the redox state of one of the two cysteines, Cys-295, within the b=
domain was altered between the fully reduced and the auto-oxidized state of PDI while the
other b= domain cysteine remained fully reduced. An interesting mono- and dioxidation
modification of an invariable tryptophan residue, Trp-35, within the active site was also
mapped by tandem mass spectrometry. Our findings indicate that ICAT methodology in
conjunction with mass spectrometry represents a powerful tool to monitor changes in the
redox state of individual cysteine residues within PDI under various conditions. (J Am Soc
Mass Spectrom 2007, 18, 260–269) © 2007 American Society for Mass SpectrometryProtein disulfide isomerase (PDI), a member of thethioredoxin superfamily of redox proteins, is anenzyme responsible for disulfide bond formation
and isomerization [1, 2], redox-dependent chaperone
function [3, 4] and S-nitrothiols denitrosation activity
[5]. Originally, PDI was identified in the lumen of the
endoplasmatic reticulum [6, 7] and subsequently de-
tected at additional locations, such as the cell surface
and the cytosol [8]. In the case of secreted PDI, it has
been demonstrated to control the redox state of certain
cell-surface proteins [9]. Furthermore, PDI was identi-
fied as a subunit of prolyl 4-hydroxylase [10, 11] and
microsomal triglyceride transfer protein [12, 13], execut-
ing different functions than in its monomeric state.
PDI comprises four domains, a , b , b = ,  and a = [14]
and an acidic region designated c [15–17] (Figure 1a).
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doi:10.1016/j.jasms.2006.09.023The two thioredoxin domains of PDI [18], a and a = ,
each contain an active site with a consensus sequence
W C GHC K, which are separated by two thioredoxin-
like domains b and b=. The multi-domain structure of
PDI is required to catalyze thiol-disulfide exchange
events and effect folding by inducing conformational
changes in the substrate protein [19]. Recently, the
crystal structure of yeast PDI was elucidated and the
structure revealed thioredoxin domains arranged in a
shape of a twisted “U” with the active sites facing
each other across the “U” [20].
Each PDI molecule contains six cysteine residues.
Four of them have been shown to participate in the
redox activity and are present as two vicinal thiol
groups within each active site. Multiple studies have
investigated the relative redox/catalytic contribu-
tions of the two thioredoxin active sites, and have
suggested that they do not have equivalent catalytic
properties [16, 21]. Furthermore, the NMR structure
of human PDI a domain identified Cys-36, as acces-
sible and exposed while Cys-39, as buried and con-
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261J Am Soc Mass Spectrom 2007, 18, 260–269 REDOX STATE ANALYSIS OF PDI WITH ICAT-BASED MSstrained [22]. In addition, the crystal structure of
yeast PDI is consistent with the view that the two
cysteines within the a domain are primarily in the
oxidized state (modeled as a mixture of oxidized to
reduced state at 0.8 to 0.2, respectively) and the
cysteines within the a = domain are in a reduced state
[20]. The function and regulation of the redox states
of the other two cysteine residues present within the
b= domain of human PDI, remains unclear.
The redox state of the active site cysteines dictates
the type of reaction PDI will catalyze. Introducing
disulfide bonds into a protein substrate requires the
presence of a disulfide active site, while rearranging
disulfide bonds within a protein substrate requires
the presence of a dithiol active site [1, 21, 23].
Therefore, the dithiol/disulfide balance within the
active sites is required for effective oxidation or
Figure 1. Schematics of ICAT strategy. (a) A sch
Domains a, b, b=, and a= share a common thiore
WCXXC active site. Position of all six cystein
Bacterially expressed, purified human His-PDI w
by Coomassie blue stain. Lane 1, PDI control pur
with 5x excess DTT); lane 3, auto-oxidized H
phosphate buffer for 1 h at room-temperature). (
PDI was reduced and immediately labeled w
temperature to allow auto-oxidation and subse
processed as described in the Materials and Medisulfide formation on PDI substrates [23]. Further-more, alterations of this redox state balance of PDI
underlie different pathological conditions. For exam-
ple, it has been observed that upon activation/aggre-
gation of resting platelets, the amount of reduced
dithiols on cell surface PDI increased approximately
3-fold, thus implying that thiol groups are critical for
platelet aggregation [24].
Common approaches to analyze thiol oxidation
states include spectrophotometric and fluorescence-
based assays [25], however, these only provide infor-
mation regarding the average number of modified
cysteine residues, not their exact identity. Here, we
present a method that uses isotope-coded affinity tag
(ICAT) based method in conjunction with mass spec-
trometry (MS) [26, 27] to detect and quantitate rela-
tive dynamic changes in the thiol oxidation state of
individual cysteine residues in recombinant human
tic model of domain architecture of human PDI.
n fold, but only the a and a= domain have the
sidues within human PDI is highlighted. (b)
parated using SDS-PAGE (10%) and visualized
ed from Sigma; lane 2, reduced His-PDI (treated
I (following reduction, PDI was incubated in
hematic presentation of ICAT labeling protocol.
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is-PD
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262 KOZAROVA ET AL. J Am Soc Mass Spectrom 2007, 18, 260–269In addition to the detection of the redox status of the
active site cysteines, we will offer data indicating
redox regulation of Cys-295 present within the b=
domain. Also, a novel oxidation modification on an
invariable tryptophan residue, Trp-35, adjacent to the
cysteine residues within the active site, will be pre-
sented.
Materials and Methods
Purification of Protein Disulfide Isomerase
His-PDI was expressed and purified as described pre-
viously [5]. Protein quantification was performed using
the Bradford assay [28] and protein purity was ascer-
tained by SDS-PAGE.
PDI Reduction and Spontaneous Auto-Oxidation
Bacterially expressed human His-PDI (100 g) was
fully reduced with 5 molar excess of DTT for 2 h at
room temperature. The DTT was removed during
gel-filtration on Sephadex G-25 in 100 mM phosphate
buffer, pH 7. Immediately after separation, the reduced
PDI was acetone precipitated and labeled with light
12C-ICAT reagent (Applied Biosystems, Foster City,
CA). For spontaneous auto-oxidation, PDI was incu-
bated for 1 h at room temperature following the reduc-
tion with DTT and gel-filtration. Subsequently, this
sample was also acetone precipitated and labeled with
heavy 13C-ICAT reagent (Applied Biosystems).
ICAT Labeling of Reduced and Auto-Oxidized PDI
PDI containing samples were prepared as described
above and ICAT labeling and purification of labeled
peptides was performed following the provided pro-
tocol from Applied Biosystems. Experiments were
performed three times to ensure reproducibility of
the results. Briefly, reduced and auto-oxidized PDI
was labeled with 12C-ICAT and 13C-ICAT reagents,
respectively, for 2 h at 37 °C. After alkylation with the
iodoacetamide-based ICAT reagent, the two samples
were mixed together and subjected to digestion with
Endoproteinase Glu-C for 12 h at 25 °C. Peptides were
desalted using a cation exchange cartridge provided
in the Applied Biosystems kit, and biotin labeled
peptides were purified using an avidin affinity car-
tridge present in the kit. Peptides were subsequently
dried and resuspended in the cleavage reagent to
release the labeled peptides from the biotin moiety by
incubation for 2 h at 37 °C. Subsequently, peptides
were dried and resuspended in 1% formic acid. All
samples were desalted using micro-C18 ZipTips (Mil-
lipore, Billerica, MA) before MALDI MS analysis.HPLC Separation of ICAT Labeled Peptides
ICAT labeled peptides were separated on a LC Pack-
ings nanoflow HPLC system (nano-LC) (LC Packings,
Sunnyvale, CA) with a Zorbax 300 SB C18 column (75
m  150 mm, 3.5 m particles) (Agilent Technolo-
gies, Palo Alto, CA) at a flow rate of 300 nL/min.
These peptides were separated using multi-step lin-
ear gradient of 0 to 30% B in the first 10 min, followed
by 30 to 45% B for 37 min, 45 to 60% B for 5 min and
100% B for 6 min (mobile phase A, 3% acetonitrile,
0.1% trifluoroacetic acid; mobile phase B, 90% aceto-
nitrile, 0.1% trifluoroacetic acid). Column effluent
was mixed with MALDI matrix (2 mg/ml -cyano-4-
hydroxycinnamic acid, 10 mM ammonium dihydro-
gen phosphate in 50:49:1 water/isopropyl alcohol/
acetic acid) through a mixing tee and spotted
automatically with a Probot (LC Packings) onto a
192-well MALDI target plate. The matrix was deliv-
ered to the mixing tee at a flow rate of 1.2 L/min.
Mass Spectrometry Analysis
ICAT labeled peptides were analyzed by MALDI-TOF
MS (DE-Pro Voyager, Applied Biosystems) and
MALDI-TOF/TOF (4700 Proteomics Analyzer, Applied
Biosystems/MDX Sciex). For the MALDI-TOF MS anal-
ysis, the purified labeled peptide sample (1:1 matrix
solution -cyano-4-hydroxycinnamic acid) was spotted
onto a MALDI target plate and analyzed in reflector
mode. For the MALDI-TOF/TOF analysis MS and
MS/MS spectra were acquired in positive ion reflector
mode. MS survey scans were acquired first for each
MALDI well and the ions of interest were selected, with
the time ion gate set at 3 Da (), for MS/MS analysis.
Results and Discussion
ICAT Labeling of PDI
An ICAT-labeling approach in combination with
mass spectrometry was developed for the purpose of
quantitating changes in the redox state of human
His-PDI under various conditions, since only free
thiols will react with the iodoacetamide-based ICAT
reagent. Bacterially expressed human PDI was puri-
fied to near homogeneity by nickel chromatography
(Figure 1b). To assess if PDI can be labeled with ICAT
reagent, following reduction with excess reducing
agent, the free thiol groups on cysteine residues
(cysteine-SH) were initially incubated with acid-
cleavable light 12C-ICAT reagent only. The ICAT-
labeled protein was digested with Glu-C to generate
unique peptides corresponding to each active site.
The [MH ] 2147 m/z ion represents the peptide
containing the active site within the a domain,
FYAPWC36GHC39KALAPE, containing two ICAT la-
bels (molecular mass 227 Da per one ICAT-tag)
(Figure 2a). This indicates that both cysteines within
263J Am Soc Mass Spectrom 2007, 18, 260–269 REDOX STATE ANALYSIS OF PDI WITH ICAT-BASED MSthe a domain were in the reduced state and thus
susceptible to labeling with the ICAT alkylating agent
(confirmed by analysis of MS/MS fragment ion se-
ries, as described below). Importantly, we did not
detect a peak at [MH] 1924 m/z, which would
correspond to only one ICAT-labeled cysteine resi-
due. Similarly to the a domain active site, a peptide
fragment representative of the a= domain active site at
Figure 2. Reduced PDI labeled with light 12C-I
ICAT-labeled Glu-C digested peptides from PDI
domain active site with both Cys residues ICAT
to the a= domain active site with both Cys residue
presented in tabulated form, including the th
modification with corresponding detected ions,
the Cys-326 present in the b= domain while fragm
2579 m/z represent various miscleavages of the se
(range 2135 to 2195 m/z) showing the ions corres
domain active site peptide.
Table 1. Recombinant human PDI ICAT-labeled peptides.
No. Start End Cys Sequence
1 325 331 326 FCHRFLE
2 294 304 295 ECPAVRLITLE
3 294 306 295 ECPAVRLITLEEE
4 31 45 36,39 FYAPWCGHCKALAPE
5 287 306 295 FFGLKKEECPAVRLITLEEE
6 375 395 380,383 FYAPWCGHCKQLAPIWDKLGE[MH] 2916 m/z was modified with two ICAT
labels. However, further analysis was complicated
with the inability of reproducibly detecting this
peptide. This implies that under these conditions, cys-
teine residues within the a= domain peptide
FYAPWC380GHC383KQLAPIWDKLGE, are either bur-
ied and inaccessible to the ICAT moiety or exist pre-
dominantly in their oxidized form, in agreement with
reagent. (a) Full scan MALDI-TOF spectrum of
[MH] 2147 m/z fragment corresponds to the a
led. The [MH] 2916 m/z fragment corresponds
T labeled. The additional peptide fragments are
ical mass prior to Cys modification and after
he fragment at [MH] 1178 m/z corresponds to
at [MH] 1470 m/z, [MH] 1728 m/z, and [MH]
ce containing Cys-295. (b) Enlargement from (a)
ing to addition of 16 Da and 32 Da on the a
ass (monoisotopic)
(m/z)
12C-ICAT-modified
(m/z) calculated
12C-ICAT-modified
(m/z) observed
951.5 1178.6 1178.8
1243.6 1470.7 1470.9
1501.8 1728.9 1729.0
1692.7 2147.0 2147.1
2351.2 2578.3 2579.3CAT
. The
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quen
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ICAT modifications.
In addition, peptide fragments corresponding to
the two remaining cysteine residues of the PDI within
the b = domain were also detected (Figure 2a, and
Table 1). Numerous peptides were detected encom-
passing the ICAT-labeled cysteine at position 295,
specifically EC295PAVRLITLE ([MH
] 1470 m/z) and
two peptides corresponding to additional miscleav-
ages ([MH] 1729 m/z and [MH] 2579 m/z). The
[MH] ion detected at 1178 m/z corresponded to the
other cysteine within the b= domain, Cys-326, within
the FC326HRFLE peptide.
Mass spectrometric studies to analyze PDI have
been performed in the past. An alternative to the
ICAT-based labeling method is alkylation of the
cysteine residues with N-ethylmaleimide (NEM) [29].
In parallel to the ICAT labeling described herein, we
also modified PDI exposed to reducing conditions
with NEM. Fragments corresponding to active sites
modified with one or two NEM adducts (125 Da per
NEM label) were detected (data not shown). In con-
trast, the ICAT-modified active site peptides repro-
ducibly produced only peptides labeled on both
cysteine residues. Another cysteine alkylating re-
agent, the episulfonium ion derived from S-(2-chlo-
roethyl)glutathione (CEG) has been identified to
modify only one cysteine residue within each active
site of rat PDI, Cys-36 and Cys-380 [30]. In addition,
cysteine residues of PDI were indicated to be modi-
fied by the thiol reactive lipid aldehyde 4-hy-
droxynonenal (4-HNE) in rat livers fed a combination
of high-fat and ethanol diet [31], although the modi-
fied cysteines were not resolved. Overall, these dif-
ferent thiol reactivities may be due to incomplete
labeling caused by various degrees of hydrophobicity
and hydrophilicity of the modifying reagent, result-
ing in limited access to buried and solvent inaccessi-
ble regions within PDI. We did not detect any singly
labeled vicinal thiols in the active site, indicating the
structural nature of the ICAT reagent is capable of
reacting with all of the cysteine residues of PDI when
they are present in their free thiol form.
Further analysis of the peptide corresponding to
the a domain active site indicated two sequential
peaks (each 16 Da apart) adjacent to the monoisotopic
mass of [MH ] 2147 m/z (Figure 2b). These modified
light-ICAT labeled peptides would likely complicate
the analysis when light and heavy ICAT-modified
samples were to be compared. Specifically, the 12C-
(light, addition of 227 Da per one ICAT-tag) and
13C-(heavy, addition of 236 Da per one ICAT-tag)
reagents have been designed to differ by 9 Da per
labeled cysteine residue for quantitation purposes
[27]. This would result in an addition of 18 Da when
two ICAT labeled cysteines are present within the
active site in the a domain. Therefore, due to isotopic
interference, the discrimination between the 16 Da
(light ICAT-label and modified peptide ([MH] 2163m/z)) and the  18 Da (heavy ICAT-label and unmod-
ified peptide ([MH] 2165 m/z)) peptides would be
challenging.
To resolve this issue, ICAT-labeled peptides were
fractionated using reverse-phase chromatography
(Figure 3). The column elution profile indicated that
all of the modified peptides were significantly re-
solved from each other (Figure 3a), and in expected
order. The peptide corresponding to the active site
within the a domain labeled with two light ICAT-tags
and modified by  32 Da eluted first (Figure 3b),
followed by the peptide modified by  16 Da (Figure
3c), whereas the most hydrophobic, nonmodified
peptide eluted last (Figure 3c).
Tryptophan Oxidation Adjacent to the Active Site
Cysteine
MS/MS analysis identified the peptide at [MH] 2147
m/z to correspond to the a domain active site frag-
ment, FYAPWC36GHC39KALAPE. This peptide con-
tains two ICAT labels, one per cysteine residue, as
determined from the y6-y10 series, the y12 fragment,
and the b8 ,b10-b14 series (Figure 4a). Further analysis
of the fragment ion series indicated that the modified
residue on the peptide at 2163 m/z and the peptide at
2179 m/z was Trp-35. Specifically, the addition of 16
Da ([MH] 2163 m/z) was consistent with tryptophan
mono-oxidation (hydroxytryptophan) (Figure 4b)
and the addition of 32 Da ([MH] 2179 m/z) was
due to the tryptophan dioxidized form (N-
formylkynurenine) (Figure 4c).
This is an intriguing modification since Trp-35 is
located within the a domain active site immediately
adjacent to the active site cysteines. It is possible, that
this modification was the result of MS sample prep-
aration. However, it has been argued that tryptophan
oxidation is not a considered mass spectrometry
encountered artifact, like methionine oxidation [32,
33] and guanidination [34]. Additionally, doubly ox-
idized tryptophan was identified in a subset of mito-
chondrial proteins predominantly associated with
redox metabolism [33] and in the chaperone  -crys-
tallin from bovine lens tissue exposed to Fenton
chemistry [35]. Sequence analysis of the residue sur-
rounding Trp-35 within PDI suggests similarity with
these other proteins modified in vivo by tryptophan
oxidation.
The susceptibility of the active site tryptophan to
oxidation was an unexpected result. In addition, the
location of this tryptophan residue immediately adja-
cent to the active site cysteines suggests that tryptophan
oxidation could potentially play a role in regulating PDI
catalysis. We are currently pursuing potential oxidation
sources and the structural/catalytic consequences of
this modification.
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of PDI Active Site
We have previously shown that PDI undergoes auto-
oxidation in the absence of reducing agents [5]. To
further characterize and definitively identify the cys-
teine residues altered during auto-oxidation, the
ICAT strategy was used to quantify changes in the
redox state of PDI. Specifically, reduced PDI was
labeled with the light 12C-ICAT reagent, while auto-
oxidized PDI was labeled with the heavy 13C-ICAT
reagent (Figure 1c). These samples were subsequently
Figure 3. Separation of the modified 12C-IC
separation of the Glu-C digested, ICAT label
Asterisks indicate elution positions for HPLC fr
analysis of peptides separated by nano-LC. The d
2197 m/z), followed by singly modified peptide
peptide ([MH] 2147 m/z) (d).combined and processed together. Upon fraction-ation of PDI peptides by nano-LC, the relative quan-
tity of thiol oxidation was assessed by MS. For the
purified a domain peptides, there was a significant
loss of ICAT labeling under these auto-oxidized
conditions. Although coeluting peptides complicated
precise quantitation, all tryptophan modified forms
displayed approximately a 5 to 1 ratio between
reduced and auto-oxidized samples when the most
abundant isotope in the two samples were analyzed
(Figure 5). The ratio of nonmodified tryptophan
containing peptides labeled with ICAT-light reagent
(([MH] 2147 m/z) can be compared to nonmodified
abeled peptides. (a) Chromatogram showing
eptides on a reverse-phase nano-LC column.
ns 55, 61, and 67 respectively. (b) MALDI-TOF
y modified peptide (32 Da) eluted first ([MH]
Da) ([MH] 2163 m/z) (c), and the unmodifiedAT-l
ed p
actio
oubl
(16tryptophan containing peptides labeled with ICAT-
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the light and heavy ICAT labeled hydroxytryptophan
containing peptides ([MH] 2163 m/z and [MH] 2181
m/z) was consistent to the tryptophan unmodified pep-
Figure 4. MALDI-TOF MS/MS analysis of th
reagent displaying tryptophan oxidation. (a) M
2147 m/z) showing the amino acid sequence an
modified peptide ([MH] 2163 m/z) was determi
modified peptide ([MH] 2179 m/z) was dete
N-formylkynurenine. Asterisks within the seque
ICAT reagent, (prime) indicates modification of
indicates modification by 32 Da (c). (d) Sequen
oxidized tryptophan; these peptides were identi
from bovine intact lens (asterisk) [35].tides (Figure 5b) as was the case of the N-formylkynure-nine containing peptides ([MH] 2179 m/z and [MH]
2197 m/z) (Figure 5a). Finally, the consistent ratio between
the tryptophan modified peptides indicates that the tryp-
tophan oxidation does not affect the redox state of the
omain active site labeled with light 12C-ICAT
S spectrum of the unmodified peptide ([MH]
sition of ICAT modifications. (b) The 16 Da
o contain a hydroxytryptophan. (c) The 32 Da
ed to contain a doubly oxidized tryptophan,
ndicates modification of cysteine residues with
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The functional significance of the two cysteine residues
within the b= domain of the human PDI has not been
completely elucidated. Point-mutation studies suggest
that these residues may not play any role in PDI
catalytic activity or substrate interaction [19, 36 –38]. We
observed that following auto-oxidation, no change in
the redox state of Cys-326 was detected ([MH] 1178
m/z and [MH] 1187 m/z) and, therefore, serves as an
internal control for the reduced and auto-oxidized
samples (Figure 6).
Figure 5. Quantitation of reduced (light 12C-
labeled) PDI following reverse-phase nano-LC se
active site containing the doubly oxidized Trp,
[MH] 2179 m/z) and auto-oxidized PDI (heavy
decrease in susceptibility to labeling. Peptides co
mono-oxidized Trp ([MH] 2163 m/z and 2181
2165 m/z) (c) were detected for reduced PDI and
patterns.Interestingly, auto-oxidation did induce changes inthe redox state of the other b= domain cysteine residue,
Cys-295. Two differential cleavage peptides containing
Cys-295 ([MH] 1470 m/z and [MH] 1479 m/z; [MH]
1728 m/z and [MH] 1737 m/z) demonstrated a dramatic
loss of ICAT reactivity under auto-oxidized conditions
(Figure 6). This result suggests, that in addition to
changes within the a domain active site of human PDI,
Cys-295 within the b= domain is also sensitive to redox
regulation. This is interesting since a study involving
chemical modification of an isolated b= domain indi-
cated that neither of these cysteine residues are likely to
-labeled) and auto-oxidized (heavy 13C-ICAT-
tion. (a) Peptides corresponding to the a domain
detected for reduced PDI (light ICAT labeled,
T labeled, [MH] 2197 m/z) displaying 5-fold
onding to the a domain active site containing the
(b) and nonmodified Trp ([MH] 2147 m/z and
-oxidized PDI displaying similar auto-oxidationICAT
para
were
ICA
rresp
m/z)
autoexchange between dithiol and disulfide states upon
479 m
268 KOZAROVA ET AL. J Am Soc Mass Spectrom 2007, 18, 260–269modulation of redox potential [37]. In contrast, based on
the crystal structure of yeast PDI, Cys-90 and Cys-97
were elucidated to form a disulfide bond [20]. These
two nonactive site cysteines are believed to destabilize
the oxidated state of the a domain active site cysteines
[39]. Our results using full length PDI implicates Cys-
295 may play a similar role as an additional redox
sensitive site, potentially capable of modulating PDI
activities.
Conclusion
This study reports detection and identification of
redox induced changes on individual cysteine resi-
dues of recombinant human PDI in response to
auto-oxidation conditions using ICAT methodology
combined with mass spectrometry. The ICAT data
presented here agree with the predicted susceptibility
to oxidation of the active site vicinal thiols within the
a domain, in that both of these cysteine residues were
reactive towards ICAT-reagent in the fully reduced
enzyme. However, the ICAT-signal of these thiols
decreased by 5-fold upon auto-oxidation. Other pre-
vious studies have implicated that the a= domain is
the higher oxidized active site [5, 21]. As predicted,
our results are consistent with these studies and
therefore demonstrates that ICAT technology is a
reliable probe for the redox state of the a domain.
However, specific conditions may exist that trans-
form the a= domain to its reduced form. Under these
specific conditions, this ICAT procedure should be
capable of detecting and quantitating this transfor-
mation.
Since PDI activity is redox dependent and dynami-
cally regulated; this approach will be useful to correlate
what conditions favor the specific redox states of PDI.
Studies are currently directed at applying this approach
to monitor and quantify the redox alterations of differ-
ent cellular pools of PDI in response to various envi-
Figure 6. Redox regulation of Cys-295 within
containing b= domain Cys residues labeled wit
containing Cys-326 from reduced (light ICAT) an
at [MH] 1178 m/z and [MH] 1187 m/z respe
mis-cleavage products ([MH] 1470 m/z and [M
in ICAT-labeling upon auto-oxidation ([MH] 1ronmental stimuli.Acknowledgments
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